Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1245/s10434-006-9185-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic Value of Immune Scoring System for Colorectal Cancer Patients with Peritoneal Metastasis.
Medicina (Kaunas)
December 2024
Peritoneal Surface Malignancy Center, Department of Surgery, Dokuz Eylul University Faculty of Medicine, 35340 Balcova, Turkey.
There is no reliable immune scoring system that can help us predict the postoperative outcomes of colorectal cancer patients with peritoneal metastases after cytoreductive surgery. In this cohort, the aims were (1) to evaluate the postoperative morbidity, mortality and surgical oncological outcomes in colorectal cancer patients with peritoneal metastasis; (2) to compare oncological and postoperative outcomes of colon cancer patients with peritoneal metastasis and rectal cancer patients with peritoneal metastasis; and (3) to assess the prognostic value of the modified Glasgow Prognostic Score (mGPS) and the CRP-albumin ratio (CAR). : A prospectively maintained database of 258 patients who underwent cytoreductive surgery for peritoneal metastases of colorectal origin between 2007 and 2024 was analyzed.
View Article and Find Full Text PDFIs There a Role for Surgery in the Treatment of Metastatic Urothelial Carcinoma?
J Clin Med
December 2024
Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson University Hospital, 195 Albany St., New Brunswick, NJ 08901, USA.
: Bladder cancer is one of the most common malignancies worldwide with over 614,000 new cases and 220,000 deaths annually. Five percent of newly diagnosed patients have metastatic disease. Metastatic urothelial carcinoma (mUC) is primarily treated with cisplatin-based chemotherapy, immunotherapy, targeted therapy, or combinations.
View Article and Find Full Text PDFStereotactic Body Therapy for Urologic Cancers-What the Urologist Needs to Know.
Life (Basel)
December 2024
Department of Surgery, Peter MacCallum Cancer Centre, The University of Melbourne, Parkville, VIC 3052, Australia.
Background: stereotactic ablative body radiotherapy (SABR) is a disruptive radiation therapy technique which is increasingly used for the treatment of urologic cancers. The aim of this narrative review is to provide an overview on the current landscape of SABR in urologic cancers and highlight advancements on the horizon.
Methods: a narrative review of the contemporary role of SABR in urologic cancers is conducted.
Safety and Efficacy of Initiating Parenteral Nutrition at Home, Home Start PN, in Advanced Peritoneal Metastasis.
Cancers (Basel)
December 2024
Departments of Surgery, Surgical Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Background: Patients with peritoneal carcinomatosis often experience intestinal failure throughout the course of their disease, and total parenteral nutrition (TPN) can be used as a temporary solution or as a bridge to definitive cytoreductive surgery. Guidelines for TPN are well established for inpatients and in 2014, guidelines were established for the initiation of TPN for outpatients in a home setting. However, the safety and efficacy of home start TPN in advanced oncology patients remain unknown.
View Article and Find Full Text PDFEfficacy and Insights from an Extensive Series of Cytoreductive Surgery for Peritoneal Neoplasms: A High-Volume Single-Center Experience.
Cancers (Basel)
December 2024
General Surgery Department, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Advances in cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC) have improved outcomes for selected patients with peritoneal surface malignancies (PSMs). This retrospective study analyzed 743 PSM patients treated at Fondazione Policlinico Universitario Agostino Gemelli from January 2016 to February 2024. The primary aim was to assess median overall survival (mOS), median disease-free survival (mDFS), and median progression-free survival (mPFS) stratified by tumor origin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!